Blog

Clean Max Enviro Energy Solutions shares rose more than 5 per cent in intraday trade on Monday, 28 September 2026, defying broader market weakness, after a block deal saw 8.6 million shares of the company change hands. The move came even as the benchmark Nifty 50 was down more than 1 per cent during the session.

As of 10 am, Clean Max Enviro Energy Solutions shares were trading 3.2 per cent higher at ₹1,439 on the NSE, making it the most active stock on the exchange by traded value.

What Happened in the Block Deal

According to Bloomberg data, a total of 8.6 million shares of Clean Max Enviro Energy Solutions changed hands in a single block on Monday. Further details of the parties involved were not immediately available at the time of the trade.

Media reports indicated that Augment India Holdings may have sold more than 7 per cent of its total stake in the company for approximately ₹1,062 crore, at a floor price of around ₹1,250 per share. According to NSE data, around 12 million shares of the company changed hands overall during the session, amounting to ₹1,573.34 crore in traded value.

Parameter	Details
Shares Traded in Block	8.6 million shares
Reported Seller	Augment India Holdings (media reports)
Reported Stake Sold	More than 7% of total holding
Reported Deal Value	About ₹1,062 crore
Reported Floor Price	About ₹1,250 per share
Total NSE Volume (Session)	About 12 million shares, ₹1,573.34 crore
Stock Price (10 am)	₹1,439, up 3.2%
Comparison to Nifty 50	Nifty down over 1% at the same time

How the Stock Performed Against the Broader Market

The Nifty 50 was down 265 points, or 1.15 per cent, at 23,870 around the time Clean Max Enviro’s stock was trading higher, underscoring how sharply the counter diverged from the broader market trend on the day. The stock’s status as the most active counter on the NSE by value reflected the scale of trading activity concentrated in the name during the session.

Harish Jujarey, AVP equity research at Prithvi Finmart, said the stock remains within a broader consolidation range despite Monday’s intraday move of 5-6 per cent, and noted that its daily chart is forming a pattern that some technical analysts read as suggesting further upside is possible if a breakout occurs. Such chart-based observations reflect one analyst’s reading of price action and are not a guarantee of how the stock will move.

• Clean Max Enviro rose over 5% intraday while the Nifty 50 fell more than 1%.
• The block deal involved 8.6 million shares, with total session volume around 12 million shares.
• Media reports point to Augment India Holdings as the likely seller of the block.
• The company’s identity as India’s largest renewable energy solutions provider for commercial and industrial clients adds context to investor interest in the stock.

About Clean Max Enviro Energy Solutions

Clean Max Enviro Energy Solutions describes itself as the largest renewable energy solutions provider for the commercial and industrial sector in India. The company made its stock market debut on Dalal Street in March 2026.

At current levels, the stock trades well above its IPO price of ₹1,053, roughly 37 per cent higher. The company’s most recent quarterly results showed a sharp improvement in profitability: revenue for the quarter ended June 2026 (Q1 FY27) rose more than 100 per cent year-on-year to ₹832 crore, EBITDA increased 74 per cent to ₹494 crore, and the company swung to a net profit of ₹55 crore from a net loss of ₹17 crore in the same quarter a year earlier.

What Investors Should Watch Next

The identity of the buyer in Monday’s block deal has not been officially confirmed, and neither has a formal exchange filing detailing the transaction at the time of reporting. Investors will likely look for such a filing to confirm the seller’s identity and the exact terms of the trade.

• Confirmation of the buyer and seller through a formal exchange disclosure
• Whether the reported stake sale by Augment India Holdings, if confirmed, signals a broader change in shareholding pattern
• The stock’s behaviour in subsequent sessions once the immediate block-deal reaction settles
• Continued tracking of the company’s quarterly results given its recent swing to profitability

Shareholders tracking Clean Max Enviro through a demat and trading account can watch for the formal bulk or block deal disclosure on the exchanges, which typically follows within a day or two of such a large trade. Investors reviewing the stock through an online trading platform may also want to note that its performance diverged sharply from the broader market on Monday, which is worth separating from the fundamentals reflected in its recent quarterly numbers.

Disclaimer: This article reports on a market event based on exchange and media data. It is for informational purposes only and does not constitute investment advice.

Shares of Jyoti CNC Automation fell as much as 3.7 per cent to ₹1,025 on the National Stock Exchange (NSE) in intraday trade on Monday, 28 September 2026, after a fire broke out at the company’s manufacturing facility in Metoda, Rajkot, over the weekend. The company said the blaze was brought under control within 30 to 60 minutes and that operations have since resumed.

Monday was the first trading session after the fire, which occurred on Saturday, 26 September. No casualties or injuries were reported in the incident.

What Happened at the Rajkot Facility

The fire broke out in the assembling unit at Jyoti CNC’s factory in Metoda GIDC, a major industrial area in Rajkot district, during the morning hours on Saturday. Thick black smoke was visible from the premises, causing alarm among employees and nearby units, and the local fire brigade was alerted and responded to the site.

Jyoti CNC said in its statement that the situation was brought under control within 30 to 60 minutes of the fire breaking out, and that no casualties or injuries occurred. The company added that operations at the facility have since resumed.

Local Gujarati media reported that the fire triggered visible panic among employees and workers at nearby units in the Metoda GIDC industrial estate as thick black smoke rose from the premises, drawing local fire brigade teams to the site before the blaze was brought under control.

Parameter	Details
Date of Fire	Saturday, 26 September 2026
Location	Metoda GIDC, Rajkot, Gujarat
Unit Affected	Assembling unit
Time to Contain	30 to 60 minutes
Casualties or Injuries	None reported
Operational Status	Resumed
Stock Reaction (Monday, NSE)	Fell as much as 3.7% to ₹1,025

How the Stock Reacted on Monday

Monday, 28 September, was the first trading session since the fire, and investors turned bearish on the stock in early deals. Jyoti CNC shares fell as much as 3.7 per cent to touch ₹1,025 on the NSE in intraday trade, before the broader tone of the session continued to weigh on sentiment.

The reaction reflects investor caution around potential disruption to the company’s manufacturing operations, even though Jyoti CNC has stated that the fire was contained quickly and that operations have resumed. The stock’s fall came against a backdrop of broader market weakness on Monday, with the Sensex and Nifty both trading lower during the session.

• The fire broke out on Saturday, 26 September, in the assembling unit at Rajkot.
• Jyoti CNC says the fire was contained within 30 to 60 minutes with no casualties.
• Operations at the facility have resumed, according to the company.
• The stock fell as much as 3.7% in Monday’s session, its first trading day after the incident.

What Jyoti CNC Does

Jyoti CNC Automation is a manufacturer of simultaneous 5-axis CNC machines and a range of computer numerical control machine tools, serving sectors including aerospace, defence, automotive and general engineering. The company’s manufacturing base is centred in Rajkot, Gujarat, where it has operated since its founding.

The Metoda GIDC facility affected by the fire is part of the company’s broader manufacturing footprint in the region, which includes multiple production units supporting its CNC machine and component output. Jyoti CNC holds roughly a 10 per cent share of India’s CNC machine manufacturing market and employs about 2,700 people.

For the quarter ended 30 June 2026 (Q1 FY27), the company reported consolidated revenue of ₹508.5 crore and consolidated profit after tax of ₹57.1 crore, with its French subsidiary facing interim restrictions during the period. The fire comes just ahead of Jyoti CNC’s annual general meeting, scheduled for Wednesday, 30 September 2026, at the company’s Lodhika GIDC premises in Rajkot district, where shareholders may seek an update on the incident.

What Investors Should Watch Next

Jyoti CNC has not disclosed a specific financial or production impact from the fire beyond confirming that operations have resumed. Investors and analysts will likely look for further detail in the company’s upcoming disclosures on whether the incident caused any measurable disruption to output or delivery timelines.

• Any formal exchange filing detailing the cause and extent of the fire damage
• Whether the incident affects near-term production or delivery schedules
• Commentary on the incident, if any, in the company’s next quarterly results
• How the stock recovers in subsequent sessions once the immediate reaction settles

Shareholders holding Jyoti CNC in a demat and trading account can watch for a formal exchange filing on the incident, since the company’s public statement so far has been limited to confirming containment and resumption of operations. Investors tracking the stock through an online trading platform may also want to separate Monday’s fire-related reaction from the broader market weakness that affected most stocks during the session.

Disclaimer: This article is based on company statements and media reports on the incident. It is for informational purposes only and does not constitute investment advice.

Shares of the National Stock Exchange of India (NSE) fell below their ₹1,785 issue price for the first time since listing, hitting an intraday low of ₹1,761 on the BSE on Monday, 28 September 2026. The stock is now trading more than 6 per cent below the ₹1,878 peak it touched on its listing day.

The decline came amid broader weakness across the market, with NSE among several stocks trading lower in Monday’s session. NSE shares remain in focus as investors assess the stock’s post-listing trajectory just four trading sessions after its debut.

How Far NSE Has Fallen From Its Peak

NSE listed on the BSE on 24 September 2026 at ₹1,800 per share, a premium of 0.84 per cent over its ₹1,785 issue price. The stock climbed to an intraday high of ₹1,878 on listing day before closing at ₹1,818.

By Monday, the stock had given up all of that listing-day gain and more. At around 9:26 am, NSE was quoted 1.7 per cent lower at ₹1,762, compared with a 1 per cent decline in the BSE Sensex at the same time. About 1.1 million equity shares changed hands on the BSE during the session.

Parameter	Details
IPO Issue Price	₹1,785 per equity share
Listing Price (24 Sept)	₹1,800 per equity share
Listing-Day High	₹1,878 per equity share
Monday’s Intraday Low	₹1,761 per equity share
Fall From Listing-Day High	About 6.2%
Fall Below Issue Price	About 1.3% at the day’s low
Shares Traded (BSE, by 9:26 am)	About 1.1 million equity shares

This marks the first session in which NSE has traded below its issue price since its market debut four sessions earlier. In the previous session, the stock had already shown signs of cooling, trading about 0.56 per cent lower and dipping to an intraday low of ₹1,790 on the BSE, marginally above the listing price at the time.

Since its debut, NSE’s market capitalisation has contracted by more than ₹12,000 crore. The company finished its first trading day valued at roughly ₹4.5 lakh crore, a figure that had eased to about ₹4.37 lakh crore during Monday’s session as the stock extended its slide.

What’s Driving the Broader Weakness

NSE’s decline has come alongside a wider market sell-off rather than any company-specific announcement. The BSE Sensex itself was down about 1 per cent at the same point in Monday’s session, meaning NSE’s fall was roughly in line with, though somewhat sharper than, the overall market move.

• NSE listed at a 0.84% premium to its issue price on 24 September.
• The stock’s listing-day high of ₹1,878 has not been retested since.
• Monday’s low of ₹1,761 is below the ₹1,785 issue price for the first time.
• The move coincides with a broader decline in the Sensex and Nifty this week.

What Brokerages Have Said About NSE’s Valuation

Angel One, in commentary cited alongside the stock’s Monday move, pointed to NSE’s dominant market position, higher revenue and profitability, and strong market share in equity derivatives as factors providing comfort on the exchange operator’s business quality, even as the stock corrects from its listing-day highs.

The brokerage also flagged that NSE derives a significant portion of its revenue, 78.65 per cent in FY26, from transaction charges, with options and futures trading among the key contributors. That concentration makes the company’s financial performance sensitive to any decline in trading volumes caused by regulatory tightening on derivatives, a higher securities transaction tax (STT), a broader economic slowdown, or disruptions to its own operational and IT infrastructure.

What This Means for NSE Shareholders

For investors who received allotment in the NSE IPO, the stock trading below its issue price for the first time is a milestone worth noting, even if it reflects broader market conditions as much as anything specific to NSE. Retail investors who applied at the ₹1,785 issue price are now sitting on a paper loss at the day’s lows, having briefly been in the money after the listing-day pop.

• The current move reflects a broader market correction, not a company-specific disclosure.
• NSE’s revenue remains concentrated in transaction charges from derivatives trading.
• Regulatory changes affecting options and futures volumes are a key variable to watch.
• The stock’s behaviour around the ₹1,785 issue price level may be watched closely in coming sessions.

Shareholders tracking NSE through a demat and trading account can watch how the stock behaves around the ₹1,785 issue-price level in the coming sessions, since a sustained move below that level would mark a shift from the stock’s early post-listing pattern. Investors reviewing the position through a trading platform may also want to track NSE’s own disclosures on trading volumes and derivative segment activity, given how directly the brokerage commentary ties the company’s earnings to that business line.

Disclaimer: Brokerage views cited are those of the respective firm and are not endorsed by Findoc. This article is for informational purposes only and does not constitute investment advice.

Sun Pharmaceutical Industries has signed a global licensing agreement with US-based LIB Therapeutics for lerodalcibep, a once-monthly drug used to lower “bad” cholesterol, giving it exclusive rights to commercialise and manufacture the medicine outside the US and China. The company disclosed the deal in an exchange filing on Monday, 28 September 2026.

The agreement gives Sun Pharma access to a $3.7 billion market for PCSK9 inhibitors, a class of cholesterol-lowering medicines, outside the US and China. Sun Pharma shares are in focus following the announcement.

What the Licensing Deal Covers

Under the agreement, Sun Pharma gets exclusive rights to commercialise and manufacture lerodalcibep worldwide, excluding the US and China. The company will also be responsible for pursuing regulatory approvals in licensed territories where the drug has not yet been approved.

LIB Therapeutics will receive an upfront payment, future milestone payments, and royalties based on net sales in the licensed territories. Other financial terms of the deal remain confidential.

Parameter	Details
Drug	Lerodalcibep, a once-monthly PCSK9 inhibitor
Brand Name (EU)	Lyrokaul
EU Approval Date	21 September 2026
Territory Licensed to Sun Pharma	Worldwide, excluding the US and China
Target Market Size (Ex-US, Ex-China)	$3.7 billion (12 months to Q2 2026)
Market Growth Rate	38% CAGR over the preceding two years
Europe’s Share of the Market	$2.9 billion
Dosage Form	300 mg subcutaneous injection, once monthly

What the Drug Does

Lerodalcibep is a once-monthly PCSK9 inhibitor designed to lower low-density lipoprotein cholesterol (LDL-C), commonly referred to as “bad” cholesterol. In the European Union, it is approved under the brand name Lyrokaul for adults with hypercholesterolaemia and mixed dyslipidaemia, administered as a 300 mg subcutaneous injection once a month.

In the United States, the drug is separately approved under the brand name Lerochol as an adjunct to diet and exercise, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. That US approval and the Chinese market are excluded from Sun Pharma’s licensing rights under this deal.

• Sun Pharma gets exclusive rights to commercialise and manufacture lerodalcibep outside the US and China.
• The drug received European Union approval on 21 September 2026, just days before this licensing deal.
• LIB Therapeutics will earn an upfront payment, milestones and net-sales royalties from the arrangement.
• The addressable market has grown at a 38% compound annual rate over the past two years.

Why This Market Matters

According to IQVIA data cited by the companies, the PCSK9 inhibitor market outside the US and China reached $3.7 billion in the 12 months ended Q2 2026, growing at a 38 per cent compound annual growth rate over the preceding two years. Europe alone accounted for $2.9 billion of that market during the period.

PCSK9 inhibitors work through a different mechanism than statins, the more commonly prescribed cholesterol-lowering drugs, and are typically used in patients who need additional LDL-C reduction beyond what statins alone can achieve. The category’s rapid growth reflects rising diagnosis and treatment of high cardiovascular risk patients globally.

What Sun Pharma’s Management Said

Kirti W Ganorkar, managing director of Sun Pharma, said the once-monthly dosing of lerodalcibep, combined with its LDL-C reduction, small injection volume and six-month ambient storage, simplifies treatment and offers greater convenience for patients.

Evan Stein, chief operating and scientific officer and co-founder of LIB Therapeutics, said Sun Pharma’s international presence and experience in building global innovative brands make it an ideal partner to bring lerodalcibep to more patients. He added that the companies aim to expand access for patients with cardiovascular disease, or at high cardiovascular risk, who need substantial additional LDL-C reductions despite existing treatment.

What This Means for Sun Pharma Shareholders

The deal adds a licensed, already EU-approved product to Sun Pharma’s innovative medicines portfolio, rather than an early-stage pipeline asset still years from market. That distinction matters for how quickly the drug could begin contributing to the company’s international business, since regulatory clearance in the European Union has already been secured.

• The deal is a licensing and manufacturing agreement, not an acquisition of LIB Therapeutics.
• Revenue contribution will depend on regulatory approvals in other licensed territories beyond the EU.
• Financial terms beyond the general royalty and milestone structure were not disclosed.
• The US and China markets remain outside Sun Pharma’s rights under this specific agreement.

Shareholders tracking Sun Pharma through a demat and trading account can watch for further disclosures on the launch timeline in Europe and other markets, since the EU approval is recent and commercial rollout details have not yet been detailed. Investors following the stock on a trading platform may also want to track how this licensing deal fits alongside Sun Pharma’s broader innovative medicines strategy in its coming quarterly disclosures.

PCSK9 inhibitors as a category have grown in relevance for patients who remain above guideline-recommended LDL-C goals despite being on statin therapy. Observational data across European countries has shown that only a minority of patients on stable oral lipid-lowering therapy achieve their risk-based cholesterol targets, underscoring the addressable need this class of drugs is designed to meet.

Indian benchmark indices fell sharply in early trade on Monday, 28 September 2026, extending losses after their longest weekly losing streak since 2020. The BSE Sensex declined as much as 900 points, or 1.21 per cent, to 72,995, while the NSE Nifty 50 lost 284 points, or 1.22 per cent, to 22,856.

Higher crude oil prices and a spike in global bond yields, following US President Donald Trump’s rejection of Iran’s latest proposal to reopen the Strait of Hormuz, dampened investor sentiment through the session. All sectoral indices traded in the red in early deals.

How Deep the Fall Went

Broader markets faced intense selling pressure alongside the benchmark indices, with both the midcap and smallcap indices down about 1 per cent each. By around 10:40 am, the Sensex had extended its fall to 935.64 points, or 1.27 per cent, trading at 72,960, while the Nifty slipped to 22,841, down about 300 points.

Parameter	Details
Sensex Intraday Fall	Up to 900 to 936 points (about 1.2-1.3%), to a low near 72,960-72,995
Nifty 50 Intraday Fall	Up to 284 to 300 points (about 1.2%), to a low near 22,841-22,856
Midcap and Smallcap Indices	Both down about 1% in early trade
Brent Crude	Up 2.2% to about $106.6 a barrel
US WTI Crude	Up 1.45% to about $93.76 a barrel
US 10-Year Treasury Yield	Around 5.2%

Hindalco Industries, Max Healthcare Institute and Kotak Mahindra Bank were among the top losers on the Nifty 50 in early trade. As of 10:00 am, the Sensex was down 858.51 points, or 1.16 per cent, at 73,037.23, and the Nifty 50 was down 258.35 points, or 1.12 per cent, at 22,882.15, with the Nifty Midcap and Smallcap indices down 0.62 per cent and 0.61 per cent respectively at that point.

What’s Driving the Sell-Off

Worries over supply concerns amid the lack of a resolution to the West Asia crisis kept oil prices elevated through Monday’s session. Higher crude prices threaten to drive inflation and widen India’s current account deficit, since the country remains the world’s third-largest oil importer.

Brent crude futures rallied 2.2 per cent to $106.6 a barrel, while US WTI crude jumped 1.45 per cent to $93.76 a barrel. The moves followed President Trump’s rejection of Iran’s proposal, with Iran insisting that only diplomacy can resolve its conflict with the United States and Israel.

• The Sensex and Nifty extended losses after their longest weekly losing streak since the 2020 crash.
• Elevated Brent crude near $106 a barrel and US 10-year yields near 5.2% are cited as the main headwinds.
• Foreign portfolio investors (FPIs), buyers in July and August, turned sellers again in September.
• All sectoral indices traded lower in early deals, with broader midcap and smallcap indices also under pressure.

What Analysts Are Saying

Dr V K Vijayakumar, chief investment strategist at Geojit Investments, said Brent crude at $106 and the US 10-year yield at 5.2 per cent are strong headwinds weighing on markets. He noted that FPIs, who had turned buyers in July and August, turned sellers again in September, a scenario he said would keep the market under pressure in the near term.

The combination of elevated crude, higher global bond yields and renewed FPI selling has been a recurring theme through September, with Monday’s session extending a pattern that began building over the preceding weeks.

How This Connects to the Broader Correction

Monday’s fall builds on a period in which a large share of Nifty stocks have already corrected meaningfully from their 52-week highs, with earlier data showing 18 of the 50 Nifty constituents down more than 20 per cent from their peaks. The fresh intraday fall on Monday adds to that pressure rather than marking a new, unrelated development.

• Crude oil and bond yields remain the two most-cited triggers for the ongoing weakness.
• FPI selling flows are a variable market participants are watching closely this week.
• Broader market indices (midcap, smallcap) are moving in step with the benchmark fall.
• Stock-specific reactions varied, with some counters like Clean Max Enviro Energy defying the broader trend.

What Investors Should Track Next

For long-term investors, a sharp single-day fall driven by external triggers, oil prices and global bond yields, is different from a company-specific development, and the two call for different responses. Reviewing whether portfolio holdings are affected by sector-wide pressure (energy-sensitive sectors, rate-sensitive financials) versus stock-specific news can help make sense of a broad move like Monday’s.

Investors tracking their holdings through a demat and trading account can watch how Brent crude and US Treasury yields evolve over the coming sessions, since both were the most-cited drivers of Monday’s fall. Traders using a trading platform intraday may also want to note the elevated volatility, given the size and speed of Monday’s move relative to recent sessions.

Gold and silver prices fell sharply in both domestic and international markets on Monday, 28 September 2026, as an impasse in talks between the US and Iran kept crude oil prices elevated, strengthening expectations that the US Federal Reserve could raise interest rates further. Gold futures on the Multi Commodity Exchange (MCX) fell below ₹1.50 lakh per 10 grams for the first time in several sessions.

In the global market, gold futures on Comex fell to around $4,230 an ounce, touching a seven-week low, while silver slipped below $62.50 an ounce. The moves mark one of the sharpest single-day declines for both metals in recent weeks.

How Far Gold and Silver Have Fallen

On the MCX, the benchmark October gold contract opened ₹751 lower at ₹1,50,100 per 10 grams, against a previous close of ₹1,50,851. By the time of writing, the contract was trading ₹2,781 lower at ₹1,48,100.

Silver futures also opened weak. The benchmark December contract on the MCX opened ₹2,396 lower at ₹2,32,300 per kg, against a previous close of ₹2,34,696, and was later trading ₹6,146 lower at ₹2,28,550 per kg.

Parameter	Details
MCX Gold (October Contract)	Opened ₹751 lower at ₹1,50,100; later ₹2,781 lower at ₹1,48,100 per 10 grams
MCX Silver (December Contract)	Opened ₹2,396 lower at ₹2,32,300; later ₹6,146 lower at ₹2,28,550 per kg
Comex Gold	Opened at $4,315; later $96.60 lower at $4,224.60 per ounce
Comex Silver	Opened at $64.66; later $2.40 lower at $62.40 per ounce
Gold’s 2026 High	₹1,80,779 per 10 grams (MCX); $5,586.20 per ounce (Comex)
Silver’s 2026 High	₹4,20,048 per kg (MCX); $121.79 per ounce (Comex)

On Comex, gold opened at $4,315 an ounce against a previous close of $4,321.20, and was later trading $96.60 lower at $4,224.60. Silver opened at $64.66 an ounce against a previous close of $64.80, and was later down $2.40 at $62.40.

Why Gold and Silver Are Under Pressure

Vikram Subburaj, chief executive officer of Giottus.com, said elevated oil prices had increased inflation concerns, keeping alive expectations of further interest-rate increases in the US. A stronger dollar and higher interest rates tend to put pressure on non-interest-bearing assets such as gold, he said.

For Indian investors, movements in the rupee would also remain important this week, alongside US inflation and employment data, oil prices, the dollar and geopolitical developments, Subburaj added.

• Gold on MCX fell below ₹1.50 lakh per 10 grams for the first time in several sessions.
• Silver on MCX dropped below ₹2.30 lakh per kg during the day.
• Comex gold touched a seven-week low near $4,230 an ounce.
• Both metals remain well below their respective highs recorded earlier in 2026.

Levels Analysts Are Watching

According to Ajay Kedia, director at Kedia Advisory, gold was expected to trade in a range of ₹1,49,505 to ₹1,52,685 on Monday, while silver could trade between ₹2,29,965 and ₹2,39,565 per kg.

These ranges reflect near-term technical expectations rather than a forecast of where prices will ultimately settle, and actual moves through the session can move outside such ranges depending on how global cues develop.

Monday’s session also coincided with a broader sell-off in Indian equities, with the Sensex and Nifty both trading sharply lower amid the same set of global pressures, elevated crude oil and rising US bond yields, that weighed on bullion. Gold and silver, often seen as safe-haven assets during equity market stress, did not benefit from the stock market weakness this time, since the same rate and dollar dynamics were working against precious metals directly.

What This Means for Precious Metal Investors

Monday’s fall comes after gold and silver had rallied sharply earlier in 2026, with both metals still trading well below their peaks for the year despite the pullback. The scale of the single-day move, gold down more than ₹2,700 on the MCX and silver down over ₹6,100, reflects how sensitive bullion prices remain to shifts in US rate expectations and the dollar.

• The immediate trigger was the stalled US-Iran talks and firmer crude oil prices.
• Rising US bond yields and a stronger dollar are adding pressure on non-yielding assets like gold.
• This week’s US inflation and employment data are likely to be closely watched for further direction.
• Domestic investors should also track rupee movements, since MCX prices are quoted in rupee terms.

Investors holding gold or silver exposure through a commodity trading account can watch how prices behave around the levels flagged by analysts in the coming sessions, since a break below or a recovery from these zones would signal whether the current pullback extends or stabilises. Those tracking bullion through an online trading platform may also want to follow this week’s US economic data releases, given how directly they are expected to influence rate expectations and, in turn, gold and silver prices.

Disclaimer: Analyst views and price ranges cited are those of the respective individuals and are not endorsed by Findoc. This article is for informational purposes only and does not constitute investment advice.

Dr Lal PathLabs Ltd will acquire a 70% stake in Gujarat-based SN Genelab Private Limited for up to ₹168 crore in cash, the diagnostics company said in a regulatory filing on Thursday, 24 September 2026. The deal also includes a performance-linked earn-out capped at ₹31.5 crore.

Once the transaction is complete, SN Genelab will become a subsidiary of Dr Lal PathLabs. The company expects to close the deal on or before 30 November 2026, and Dr Lal PathLabs shares are in focus on Friday.

Dr Lal PathLabs SN Genelab Deal: Key Terms

The Dr Lal PathLabs board approved the acquisition at a meeting held between 4:40 pm and 5:11 pm IST on Thursday, after market hours. The stake will be bought from SN Genelab’s existing shareholders. Because the board met after the market closed at 3:30 pm IST, Friday is the first trading session in which Dr Lal PathLabs’ share price can reflect the announcement.

Parameter	Details
Target Company	SN Genelab Private Limited
Stake Acquired	70%
Upfront Consideration	Up to ₹168 crore
Earn-Out	Performance-linked, capped at ₹31.5 crore
Form of Payment	100% cash
Expected Completion	On or before 30 November 2026
Regulatory Approvals	None required, as per the filing
Related-Party Transaction	No

The filing states that no prior government or regulatory approval is needed for the deal. It also states that the transaction does not fall within the scope of related-party transactions.

What an Earn-Out Means in This Deal

An earn-out is an additional payment made to sellers only if the acquired business meets agreed performance targets after the deal. In this case, the extra payout is capped at ₹31.5 crore.

This structure means the total cost for the 70% stake could range up to about ₹199.5 crore if the full earn-out is paid. The specific targets that trigger the earn-out have not been disclosed in the details reported so far.

Earn-outs link part of the purchase price to future performance and keep the sellers invested in the business after it changes hands.

SN Genelab’s Business and Revenue Trend

SN Genelab was incorporated on 16 December 2013 in Gujarat. It provides diagnostic genomics services, which involve testing a patient’s genetic material to support diagnosis and treatment decisions.

The company has reported steady growth in turnover over the last three financial years:

Parameter	Details
FY24 Turnover	₹43.27 crore
FY25 Turnover	₹53.36 crore, up 23.3% year-on-year
FY26 Turnover	₹57.96 crore, up 8.6% year-on-year

Growth slowed in FY26 compared with the previous year, though turnover still rose by ₹4.60 crore. Profit figures for SN Genelab were not part of the details disclosed in the filing coverage.

By simple arithmetic, the upfront price of up to ₹168 crore for 70% implies an equity value of up to about ₹240 crore for the whole of SN Genelab, before any earn-out. That is roughly 4.1 times its FY26 turnover.

Why Dr Lal PathLabs Is Buying a Genomics Business

Dr Lal PathLabs said the acquisition is aimed at strengthening its expertise in genomics and expanding its portfolio of advanced diagnostic services. Genomics testing sits at the specialised end of diagnostics, compared with routine blood and pathology tests.

The deal also gives Dr Lal PathLabs an established genomics business in Gujarat, with a three-year record of rising turnover, instead of building the capability from scratch.

This is not Dr Lal PathLabs’ first acquisition. In October 2021, the company announced the acquisition of Suburban Diagnostics along with its second-quarter results for FY22.

What It Means for Dr Lal PathLabs Shareholders

After completion, SN Genelab’s financials will be consolidated into Dr Lal PathLabs’ accounts as a subsidiary. With the 70% stake bought from existing shareholders, the remaining 30% stays outside Dr Lal PathLabs’ ownership. That 30% will be shown as a non-controlling interest in the consolidated statements.

Investors tracking the stock can watch a few specific points over the coming months:

• Completion of the transaction by the 30 November 2026 target
• Any disclosure of SN Genelab’s profitability and the earn-out conditions
• Management commentary on genomics in upcoming quarterly results
• The contribution of specialised tests to Dr Lal PathLabs’ revenue mix

The deal is a cash acquisition, so it will use part of the company’s cash resources rather than dilute existing shareholders through new shares.

Shareholders who hold the stock in a demat and trading account can follow completion updates through company filings on BSE and NSE. Those who use an investing platform can add the stock to a watchlist to track price moves around such announcements.

Key Dates for the SN Genelab Acquisition

The main date to track is 30 November 2026, the deadline set for completing the transaction. Until then, the acquisition remains pending.

Any update on completion, final consideration paid, or earn-out targets will come through a stock exchange filing by Dr Lal PathLabs.

The Nifty 50 opened slightly lower at 23,035 on Friday, 25 September 2026, a day after the index closed at its lowest level in over five months. Thursday’s 1.64% fall, the Nifty’s biggest single-day drop since 8 July, came as Brent crude hovered near $105 a barrel and US bond yields climbed.

The BSE Sensex also started Friday’s session marginally in the red. A dip of more than 1% in crude oil prices, on hopes of a truce between the US and Iran, kept losses limited in early trade.

How Sensex and Nifty Closed on Thursday

Thursday’s session saw a broad sell-off led by banks and non-banking finance companies (NBFCs). Only three of the 50 Nifty stocks ended higher.

Parameter	Details
Nifty 50	Closed at 23,063.10, down 383.7 points (1.64%)
BSE Sensex	Closed at 73,580.54, down 1,247.7 points (1.67%)
India VIX	Closed at 12.7, up 22.8%
Market Cap of BSE-Listed Firms	Down ₹2.7 trillion (0.5%)

The Nifty’s close was its lowest since early April. India VIX, the NSE volatility index that tracks expected market swings, jumped sharply, signalling greater caution among traders.

HDFC Life Insurance, Bajaj Finance, Axis Bank and Bajaj Finserv were the top Nifty losers, falling between 4.5% and 6.2%. The total market value of BSE-listed companies fell by ₹2.7 trillion despite the listing of NSE shares on the same day.

Three Triggers Behind the Nifty’s Fall

Several pressures came together on Thursday, each hitting a different part of the market.

• Crude oil near $105: Brent November futures were up 1.8% at $104.9 a barrel on Thursday evening. India imports most of its crude, so higher oil prices raise the import bill and can feed into inflation and corporate costs.
• Rising US bond yields: The US 10-year Treasury yield rose to 5.12% on Thursday. Higher yields in the US tend to make riskier assets, including emerging market equities, less attractive to global investors.
• IRDAI’s draft commission caps: The insurance regulator’s proposal to cap commissions and lower insurers’ expense limits hit insurers, banks and NBFCs that earn fees from selling insurance.

The combination explains why financial stocks, which carry a large weight in both the Nifty and the Sensex, dragged the indices lower. PB Fintech fell 36% on the IRDAI proposal, while several lenders lost between 3% and 8% during the day.

How Friday’s Session Started

On Friday, the Sensex opened 54.62 points, or 0.07%, lower at 73,525.92. The Nifty opened 28.10 points lower at 23,035. In the pre-open session, the Sensex had briefly traded 66 points higher at 73,646.

Broader markets were mixed in early trade. The BSE Smallcap Select index rose 0.29% to 9,190.36, while the BSE Midcap Select index slipped marginally.

Market breadth on the NSE was close to even in early deals, with 1,370 stocks advancing against 1,327 declining. The Indian rupee opened 6 paise stronger at 95.90 against the US dollar, compared with Thursday’s close of 95.96.

Global Cues for Indian Markets on Friday

Brent crude fell more than 1% in Asian trading hours to around $105.7 a barrel. The decline followed reports that the US and Iran are exploring a phased path out of the war, which raised hopes of a truce.

US markets offered little support. The Dow Jones Industrial Average fell 0.31% and the S&P 500 slipped 0.02% overnight, while the Nasdaq Composite ended 0.01% higher. The US 10-year Treasury yield extended gains to 5.22%.

Asian markets were mixed as investors assessed the meeting between US President Donald Trump and Chinese President Xi Jinping. Japan’s Nikkei 225 rose 1.30%, while Hong Kong’s Hang Seng fell 1.64%. Markets in mainland China and South Korea were closed on Friday.

Parameter	Details
Brent Crude	About $105.7 a barrel, down about 1.2%
US 10-Year Treasury Yield	5.22%
Nikkei 225	Up 1.30%
Hang Seng	Down 1.64%
Rupee vs US Dollar	Opened at 95.90

What the Selloff Means for Investors

A five-month low in the Nifty reflects pressure from outside India, mainly oil and global bond yields, as well as a sector-specific shock from the insurance regulator. These are different kinds of risks, and each can change direction quickly.

For long-term investors, a volatile phase is a reason to review the asset allocation and quality of holdings rather than react to one session. Those planning to open a demat account and begin investing can use this period to understand how index moves, volatility and sector news affect a portfolio.

Intraday traders using a share market app should factor in the higher India VIX, since elevated volatility usually means wider price swings and higher margin needs on derivatives positions.

Key Things to Track Next

Indian markets will take their direction from a few clear variables over the coming sessions:

• Brent crude movement and any concrete progress on a US and Iran truce
• US Treasury yields, now above 5%
• Foreign investor flows into Indian equities
• Further clarity on IRDAI’s draft rules, open for comments until 25 October 2026

Friday’s flat opening, after Thursday’s sharp fall, leaves these factors as the main triggers to watch through the rest of the session.

AceVector Ltd, the parent company of e-commerce marketplace Snapdeal, opens its ₹420 crore initial public offering (IPO) for subscription today, Friday, 25 September 2026. The price band is ₹30 to ₹32 per share, and the issue closes on Tuesday, 29 September.

A day before opening, AceVector raised ₹189 crore from 14 anchor investors at ₹32 per share, the top of the price band. The shares are proposed to be listed on BSE and NSE, with NSE as the designated stock exchange.

AceVector IPO Key Details

The AceVector IPO is a mix of a fresh issue and an offer for sale (OFS). In a fresh issue, the company raises new money; in an OFS, existing shareholders sell part of their holding and the proceeds go to them.

Parameter	Details
IPO Dates	25 September 2026 to 29 September 2026
Anchor Book	24 September 2026, ₹189 crore raised from anchor investors
Face Value	₹1 per equity share
Price Band	₹30 to ₹32 per equity share
Lot Size	468 shares (minimum ₹14,976 at the cap price)
Issue Type	Book-built, fresh issue plus offer for sale
Total Issue Size	₹420 crore
Fresh Issue	₹287 crore
Offer for Sale	Up to 4,15,62,500 equity shares (about ₹133 crore at the cap price)
Listing Exchanges	BSE, NSE
Allotment Date	30 September 2026 (tentative)
Credit to Demat	1 October 2026 (tentative)
Listing Date	5 October 2026 (tentative)

In total, the offer covers 13,12,50,000 equity shares at the upper end of the price band. AceVector had already raised ₹13 crore in a pre-IPO round, and this amount will be adjusted against the fresh issue.

Important Dates for Snapdeal IPO Investors

The IPO timeline is short, with allotment due the day after the issue closes. Investors should keep these dates in mind:

• Anchor bidding: Thursday, 24 September 2026
• IPO opens: Friday, 25 September 2026
• IPO closes: Tuesday, 29 September 2026
• Basis of allotment: Wednesday, 30 September 2026
• Credit of shares to demat accounts: Thursday, 1 October 2026
• Tentative listing date: Monday, 5 October 2026

The listing date is tentative and will be confirmed by the exchanges. Unsuccessful applicants get their blocked funds released as part of the post-allotment process.

How the Offer Is Split Between Investor Categories

AceVector has reserved 75% of the issue for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs) and 10% for retail investors.

The small retail quota means individual investors are competing for a limited pool of shares. If the retail portion is heavily oversubscribed, allotment is decided by a lottery among eligible applicants, with most successful applicants receiving one lot.

Who Invested in the Anchor Book

AceVector allotted about 5.91 crore shares to anchor investors at ₹32 each. Anchor investors are large institutions that commit before the IPO opens and are subject to a lock-in period after listing.

Negen Undiscovered Value Fund, a Category III alternative investment fund, was the largest anchor investor with shares worth about ₹40 crore. Singularity Growth Opportunities Fund II took shares worth nearly ₹27 crore, while Turnaround Opportunities Fund was allotted shares worth about ₹20 crore.

Domestic mutual funds participated through three schemes: Helios Mid Cap Fund, Helios Small Cap Fund and Taurus Ethical Fund. Together they took 93.74 lakh shares, or 15.87% of the anchor portion, worth about ₹30 crore. The company reported no applications from insurance companies or pension funds in the anchor round.

How AceVector Plans to Use the IPO Money

Most of the fresh issue proceeds are earmarked for growing the Snapdeal marketplace. The company has laid out the following uses:

• ₹132 crore for marketing and business promotion for the marketplace business
• ₹50 crore for technology infrastructure for the marketplace business
• The balance for inorganic growth through acquisitions and for general corporate purposes

AceVector has not named any specific acquisition targets. The OFS portion does not go to the company, so only the fresh issue funds these plans.

What AceVector Does

AceVector was incorporated in September 2007 as Jasper Infotech Private Limited. It runs an asset-light digital commerce business through three segments.

The first is Snapdeal, a marketplace focused on value-conscious shoppers. The second is Unicommerce eSolutions, an e-commerce enablement software-as-a-service (SaaS) platform used by online sellers and brands. The third is Stellaro Brands, which operates consumer brands.

IIFL Capital Services, CLSA India and Systematix Corporate Services are the book-running lead managers, and MUFG Intime India is the registrar.

How to Apply for the AceVector IPO

Retail investors can bid for one lot of 468 shares or in multiples of 468. Bids can be placed through UPI via a broker, or through ASBA using net banking, where the bid amount is blocked in the bank account rather than debited.

Demat account opening and UPI linking should be completed before bidding, because allotted shares are credited only to a demat account. Investors who invest in IPO online through a trading account can bid at the cut-off price, which means they accept the final price set within the band.

Other issues also open today, including the IPOs of Orient Cables, German Green Steel and Runwal Enterprises. Investors weighing several offers should read each company’s red herring prospectus (RHP), which sets out financials, risks and objects of the issue in detail.

The Securities and Exchange Board of India (SEBI) on Thursday, 24 September 2026, approved foreign portfolio investor (FPI) participation in non-cash-settled, non-agricultural commodity derivatives. FPIs will have to exit these positions before any delivery obligation arises, a safeguard that keeps them away from the physical settlement of bullion, energy and base metal contracts.

The decision was part of a wider set of SEBI board approvals that also overhauled portfolio management rules and settlement proceedings. Shares of Multi Commodity Exchange of India (MCX) are in focus on Friday after the announcement.

What SEBI’s FPI Commodity Decision Changes

Until now, FPIs could trade only cash-settled non-agricultural commodity contracts and indices made up of such commodities. That framework has been in place since SEBI first allowed FPIs into exchange-traded commodity derivatives in September 2022.

The new approval goes further in two ways. FPIs can now trade non-agricultural index derivatives irrespective of whether the underlying contracts are cash-settled. They can also trade non-cash-settled non-agricultural commodity derivatives, which are contracts that normally end in physical delivery of the commodity.

Parameter	Details
Cash-Settled Non-Agri Commodity Contracts	Allowed earlier, remains allowed
Non-Agri Commodity Indices	Earlier allowed only where cash-settled, now allowed irrespective of underlying settlement
Non-Cash-Settled Non-Agri Contracts	Not allowed earlier, now allowed with exit required before delivery
Agricultural Commodity Contracts	Not allowed, no change announced

In simple terms, a cash-settled contract ends with a money payment based on price difference. A non-cash-settled, or delivery-based, contract can require the seller to deliver and the buyer to take delivery of the actual commodity at expiry.

The Delivery Firewall Explained

The key condition is that FPIs must close their positions in delivery-based contracts before the delivery obligation begins. This lets foreign investors trade price exposure in these contracts without handling physical gold, silver, metals or energy products in India.

SEBI said it will adopt several safeguards for this route. Operational details, such as the exact exit timelines and the effective date, have not yet been released and will matter for how quickly FPIs can start trading.

Non-agricultural commodity derivatives in India broadly cover three groups: bullion such as gold and silver, energy such as crude oil and natural gas, and base metals such as copper and zinc. Agricultural contracts remain outside the FPI route.

Why the Move Matters for MCX and Commodity Markets

SEBI’s stated aim has been to deepen institutional participation in India’s commodity derivatives market. Higher participation from large investors is generally linked to better liquidity, which makes a market more useful for hedging.

The proposal is not new. In September 2025, SEBI Chairman Tuhin Kanta Pandey said at an MCX conference that allowing FPIs in non-cash-settled, non-agricultural commodity contracts was under active consideration. Thursday’s board approval turns that proposal into a decision.

Whether volumes rise meaningfully will depend on how many FPIs use the route.

• Commodity exchanges: a wider pool of eligible participants in bullion, energy and base metal contracts.
• Domestic hedgers: potentially more counterparties in delivery-based contracts.
• FPIs: access to Indian price benchmarks, but with a mandatory exit before delivery.
• Retail traders: no direct rule change for their own positions.

Domestic participants need a commodity trading account with a broker registered for the commodity segment to trade these contracts. Traders who follow MCX gold, silver or crude contracts on an online trading platform can track open interest and volume data to see whether foreign participation picks up once the framework is notified.

Other Key SEBI Board Decisions on 24 September

The commodity decision came with a broad package of reforms. The largest was a new set of Portfolio Managers Regulations, 2026, replacing the 2020 rules.

PMS Rules Get More Room

SEBI approved a new portfolio managers route for investing in mutual fund units, called PRIM. It allows portfolio management service (PMS) providers to invest client money in direct mutual fund schemes and specialised investment funds (SIFs), through a separate investment approach with a minimum ticket size of ₹25 lakh.

Discretionary PMS providers can invest up to 10% of client assets under management in investment-grade unlisted debt securities, with client consent. PMS providers are also allowed to invest in IPOs, primary debt issuances and exchange-traded derivatives.

Investors who do not meet PMS ticket sizes can still open demat account online and buy direct mutual fund plans or apply for IPOs on their own.

Settlement Proceedings Overhaul

SEBI approved changes to the Settlement Proceedings Regulations, including a new formula for calculating settlement amounts and separate treatment of wrongful gains. It will issue a settlement notice before a show-cause notice, giving entities 60 days to file a settlement application, except where an interim order is being considered.

A fast-track settlement route will apply where the settlement amount is up to ₹10 lakh and the case involves a disclosure-related violation. Cases involving misrepresentation of financial statements or diversion of funds can now also be settled.

Advertising and Other Changes

A common advertisement code for certain regulated entities was approved. It allows celebrities in brand-level or entity-level promotion, and removes some mandatory prior approvals except for ads that carry celebrity endorsements.

SEBI also relaxed call recording requirements for research analysts dealing with institutional clients, expanded vault manager norms beyond electronic gold receipts, and approved ease-of-doing-business steps for REITs and InvITs. Changes to the accredited investor framework and to NCD listing requirements were also cleared.

What to Watch Next

SEBI’s board approval is the first step. The formal circular and amended regulations will set out the exact FPI exit timelines, other operational safeguards and the date from which the new route applies.

For commodity market participants, the next data points are the circular itself and early trading data from commodity exchanges once FPIs begin using the route. For PMS clients, the new PRIM route and IPO investment permission will become relevant once the 2026 regulations are notified.